A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...